Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sales & Earning In Brief

This article was originally published in The Tan Sheet

Executive Summary

Hi-Tech Pharmacal seeks OTC acquisitions: The pharmaceutical firm plans to bolster its current line of diabetic consumer health products with additional brand acquisitions. The OTC market is "a critical area for future growth and we are continuing to seek acquisitions to build our OTC business," said Hi-Tech Pharmacal CEO David Seltzer March 11. The Amityville, N.Y., company purchased the Mag-Ox magnesium supplement line in early March (1"The Tan Sheet" March 8, 2010, In Brief). For the November-January period, Hi-Tech grew sales in its Health Care Products division, including OTCs, 11.5 percent to $2.9 million, while overall net sales jumped 32 percent to $38.8 million

You may also be interested in...



Hi-Tech adds magnesium supplements

Hi-Tech Pharmacal acquires Mag-Ox supplement line from Blaine Pharmaceuticals, adding to the specialty pharma's OTC offerings for diabetic consumers. The $4.1 million cash transaction includes rights to magnesium supplements that generated about $3.4 million in 2009 sales, including Mag-Ox 400, Maginex and Uro-Mag. Hi-Tech said March 2 magnesium deficiency is common among diabetics and the Amityville, N.Y.-based firm expects the acquisition to be accretive and cash flow-positive soon

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Topics

UsernamePublicRestriction

Register

PS103926

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel